Supplemental Table 4 from Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion
Jessica TangNicholas PulliamAli ÖzeşAaron BuechleinNing DingHarold KeerDoug RuschHeather M. O’HaganM. Sharon StackKenneth P. Nephew
0
Citation
0
Reference
10
Related Paper
Abstract:
<p>RNA-seq genes_FC 1.2, P 0.05</p>Keywords:
Serous ovarian cancer
Table (database)
Abstract Background Ovarian cancer remains one of the most lethal malignancies in women which is typically diagnosed at a late stage and has no effective screening strategy. It is essential to explore novel biomarkers for the diagnosis and prognosis of ovarian cancer, as well as therapeutic targets. Recent studies have shown that circRNAs participate in ovarian cancer progression by regulating various processes and being able to act as potential biomarkers for ovarian cancer diagnosis and prognosis. In the present study we aimed to explore the prognostic role of circ_0078607 in high-grade serous ovarian cancer. Results The expression of circ_0078607 in 49 high-grade serous ovarian cancer and adjacent non-cancerous tissue samples were detected by quantitative real-time polymerase chain reaction (qRT-PCR). We noticed that circ_0078607 expression was significantly downregulated in ovarian cancer tissues compared with adjacent non-cancerous tissues. Besides, patients with low circ_0078607 expression exhibited parameters associated with poor prognosis, including advanced FIGO stage and higher serum CA125 level. Kaplan-Meier survival curve analysis showed that both progression-free survival and overall survival were significantly shortened in patients with low circ_0078607 expression. Cox regression model analysis showed that low expression of circ_0078607 was an adverse prognostic indicator for high-grade serous ovarian cancer patients. Conclusions Low expression of circ_0078607 might be an adverse prognostic indicator for high-grade serous ovarian cancer patients.
Serous ovarian cancer
Cite
Citations (0)
Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the cytokine interleukin-16 (IL-16) when comparing tumor transcriptomes based on progression-free survival. IL-16 was expressed at significantly lower levels in high-grade serous ovarian tumors of women with the longest progression-free survival.
Serous ovarian cancer
Progression-free survival
Tumor progression
Cite
Citations (0)
ABSTRACT The authors found that ESRRA when co-expressed at high levels with TGFβR3 may be prognostic for serous ovarian cancer overall survival in data from the Cancer Genome Atlas; however, this result was not validated in further datasets. A cell line was also identified in this study for future functional investigation of interactions between ESRRA and TGFβR3 in the context of oestrogen signaling in order to further elucidate their potential roles as prognostic biomarkers for serous ovarian cancer. FUNDING SUPPORT This work was supported by Cancer Research UK program A6689 (RB and CSWB) and the Medical Research Council (AP) CONFLICT OF INTEREST DISCLOSURES The authors have declared no conflicts of interest. AUTHOR CONTRIBUTIONS CSWB designed the study. AP, CSWB, and RB developed the methodology. AP and CSWB collected the data. AP, CSWB, and RB wrote the manuscript. CSWB is responsible for the overall content.
Serous ovarian cancer
Cite
Citations (0)
Serous ovarian cancer
Animal model
Histology
Cite
Citations (3)
Objective: To discuss the expression and diagnostic value of HE4 level in early serous ovarian cancer.Methods: HE4 and CA125 of 43 patients with serous ovarian cancer,43 patients with benign ovarian diseases and 43 health people were detected and compared.Results: HE4 and CA125 of patients with serous ovarian cancer were significantly higher than the other two groups(P0.05);and the positive rate of HE4 were significantly higher than CA125 in patients with serous ovarian cancer(P0.05).Conclusions: HE4 and CA125 showed a significantly increased expression in ovarian cancer patients,but HE4 is more sensitive in early diagnosis of serous ovarian cancer.
Serous ovarian cancer
Cite
Citations (0)
Serous ovarian cancer
Cite
Citations (0)
Serous ovarian cancer
Clinical Significance
Human genetics
Cite
Citations (10)
[Purpose] To explore the relationship between expression of CLN3 gene and its biological behaviors in ovarian serous cancer. [Methods] The expression of CLN3 in 45 cases with ovarian serous tumor (23 cases with ovarian serous cancer, 11 cases with borderline ovarian serous tumor, 11 cases with benign serous tumor) and 12 cases of normal ovarian tissue were detected by reverse-transcription polymerase chain reaction (RT-PCR) and Western blot methods. [Results] The expression of CLN3 mRNA was 3.04±0.58 in ovarian serous cancer and 1.63±0.43 in borderline ovarian serous tumor. The expressions of CLN3 mRNA in ovarian serous cancer and borderline ovarian serous tumor were significantly higher than those in benign ovarian serous tumor and normal ovarian tissue (P0.01). The expression of CLN3 mRNA in ovarian serous cancer was higher than that in borderline ovarian serous tumor (P0.01). There was significantly difference between stageⅠ/Ⅱ and Ⅲ~/Ⅳ, G1/G2 and G3, with and without ascites (P0.05). [Conclusion] CLN3 might be related to the carcinogenesis and prognosis of ovarian serous cancer and become an important biological marker for ovarian serous cancer.
Serous ovarian cancer
Ovarian tumor
Cite
Citations (0)
MILO-ENGOT-ov11 is the largest study evaluating the role of MEK inhibitors in patients with low-grade serous ovarian cancer.[1][1] While low-grade serous ovarian cancer is considered less aggressive than other subtypes of ovarian cancer, the disease affects younger women, has low response rates to
Serous ovarian cancer
Cite
Citations (1)
Abstract Background Low-grade serous ovarian cancer is a rare subtype of ovarian cancer and lack of large-scale systematic studies worldwide.This study is aimed to select the target gene and figure out the expression and clinical significance of it in low-grade serous ovarian cancer. Methods and Results The mRNA data was downloaded from the Gene Expression Omnibus (GEO), then the differentially expressed genes (DEGs) between cancer and normal tissue were screened out by R software. Under comprehensive consideration, C1orf106 was chosen as our target gene based on the significant |logFC|, known molecular function and research innovation. Immunohistochemistry and qRT-PCR both showed that C1orf106 was highly expressed in tumor tissue. Contacted with clinical information, high-expression of C1orf106 was associated with lower Body Mass Index (< 25kg/m 2 ) and no residual lesion. Kaplan-Meier analysis showed that high-expression of C1orf106 was associated with better overall survival, but may not be correlated with progression-free survival. COX regression model indicated that C1orf106 was one of the prognostic factor for low-grade serous ovarian cancer, but not independently. Conclusion C1orf106 was highly expressed in low-grade serous ovarian cancer. High expression of C1orf106 indicated a better overall survival. Therefore, C1orf106 may be one of the biomarkers with diagnostic and prognostic value in low-grade serous ovarian cancer, but the precise mechanism still needs further research.
Serous ovarian cancer
Clinical Significance
Cite
Citations (0)